	MEDICAL COVERAGE POLICY
Scott&White HEALTH PLAN — PART OF BAYLOR SCOTT & WHITE HEALTH / FirstCare HEALTH PLANS — PART OF BAYLOR SCOTT & WHITE HEALTH	**SERVICE:** Biochemical Markers of Alzheimers Disease
	Policy Number: 029
	Effective Date: 11/01/2020
	Last Review: 09/24/2020
	Next Review Date: 09/24/2021

Important note:

Unless otherwise indicated, this policy will apply to all lines of business.

Even though this policy may indicate that a particular service or supply may be considered medically necessary and thus covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. You need to consult the Evidence of Coverage (EOC) or Summary Plan Description (SPD) to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and your plan of benefits, the provisions of your benefits plan will govern. However, applicable state mandates will take precedence with respect to fully insured plans and self-funded non-ERISA (e.g., government, school boards, church) plans. Unless otherwise specifically excluded, Federal mandates will apply to all plans. With respect to Medicare-linked plan members, this policy will apply unless there are Medicare policies that provide differing coverage rules, in which case Medicare coverage rules supersede guidelines in this policy. Medicare-linked plan policies will only apply to benefits paid for under Medicare rules, and not to any other health benefit plan benefits. CMS's Coverage Issues Manual can be found on the CMS website. Similarly, for Medicaid-linked plans, the Texas Medicaid Provider Procedures Manual (TMPPM) supersedes coverage guidelines in this policy where applicable.

SERVICE: Biochemical Markers of Alzheimer's Disease

PRIOR AUTHORIZATION: Not applicable.

POLICY: Please review the plan's EOC (Evidence of Coverage) or Summary Plan Description (SPD) for coverage details.

   For Medicare plans, please refer to appropriate Medicare LCD (Local Coverage Determination). If there is no applicable LCD, use the criteria set forth below.

   For Medicaid plans, please confirm coverage as outlined in the Texas Medicaid TMPPM.

SWHP/FirstCare considers the use of biomarkers, tests and measurements in the diagnosis and management of Alzheimer's Disease to be experimental and investigational and **NOT** medically necessary.

Biomarkers, tests and measurements not medically necessary include, but are not limited to, the following:
- Apolipoprotein E
- ATP-binding cassette transporter
- Bcl-2 rs956572 polymorphism testing
- Beta amyloid 42 (BA-24, Aβ42) protein (cerebrospinal fluid and plasma)
- Beta-site amyloid precursor protein cleaving enzyme 1
- Cerebrospinal fluid (CSF) chitinase enzyme activity
- Circadian rhythm analysis
- CSF microRNAs (e.g., hsa-miR-27a-3p)
- CSF neurogranin
- CSF phosphorylated tau at threonine 181 (ptau181), tau/Aβ42, and ptau181/Aβ42
- CSF prion protein concentration
- CSF soluble amyloid precursor proteins (sAPP) level/CSF β-secretase activity
- CSF stathmin protein level
- CSF total tau (t-tau)

MEDICAL COVERAGE POLICY

SERVICE: Biochemical Markers of Alzheimers Disease

Policy Number:	**029**
Effective Date:	**11/01/2020**
Last Review:	**09/24/2020**
Next Review Date:	**09/24/2021**

- CSF visinin-like protein-1 (VILIP-1) level
- Cognitive event-related potentials (cognitive evoked potentials)
- DNA methylation profiling (brain tissue or peripheral blood)
- Electronystagmography (in the absence of signs of vertigo or balance disorder)
- Genetic testing (e.g., presenilin-1 gene [PSEN1], presenilin-2 gene [PSEN2], apolipoprotein E epsilon 4 allele, amyloid precursor gene, etc.)
- Genetic variation of mitochondrial DNA
- Homocysteine (serum level)
- INNO-BIA AlzBio3 immunoassay kit (a multiplex immunoassay that allows simultaneous quantification of amyloid-beta, p-tau, and t-tau)
- Insulin degrading enzyme polymorphisms
- Long-term measurement of cortisol
- Macular thickness
- Microtubule-associated protein tau (MAPT)
- N-terminal pro-brain natriuretic peptide (NT-proBNP)
- Olfactory screening tests
- Plasma clusterin level
- Plasma prion protein concentration
- Plasma tau
- Pituitary adenylate cyclase-activating polypeptide (PACAP)
- Red blood cell omega-3 fatty acid level 06/06/2018
- Resting state eye-closed cortical electroencephalography
- Serum ceramides
- Serum insulin-like growth factor-1 (IGF-1 also known as somatomedin C)
- Serum microRNAs
- Serum neurofilament light concentration
- Tau protein
- Transforming growth factor-beta1 (TGF-β1)
- TREM2 (triggering receptor expressed on myeloid cells 2)
- Tympanometry (in the absence of hearing loss)
- Urinary AD7c-NTP (neuronal thread protein/neural thread protein)
- Videopupillography and tropicamide drop test

OVERVIEW:

Alzheimer's disease (AD) is an irreversible, progressive brain disorder that occurs gradually and results in memory loss, unusual behavior, personality changes, and a decline in thinking ability. The Alzheimer's Foundation of America (AFA) reports that there are between 4.2 and 5.8 million people affected with AD. The incidence of AD is expected to climb as the population ages. Additionally, the Alzheimer's Association (AA) reports that there are between 200,000 and 500, 000 people with early onset disease occurring before the age of 65. The mean duration from the onset of clinical symptoms to the death of the patient has been reported to be approximately 8.5 years.

Currently the diagnosis of AD is a clinical diagnosis, focusing on the exclusion of other causes of senile dementia. The United States Preventative task force continues to support the use of clinical

MEDICAL COVERAGE POLICY

SERVICE: Biochemical Markers of Alzheimers Disease

Policy Number:	029
Effective Date:	11/01/2020
Last Review:	09/24/2020
Next Review Date:	09/24/2021

findings in diagnosis. Psycho-behavioral instruments such as the Mini-Mental State Examination (MMSE) and the Functional Activities Questionnaire are in current use. The MMSE has a sensitivity that ranges from 71 to 96 percent and a specificity range from 56 to 72 percent for dementia. The task force also concluded that current therapies, primarily medication, could only slow AD progression two to seven months and had limited effects on activities of daily living. The benefits of early screening will not be fully realized until better treatment modalities are developed.

In 1988, the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's and Related Disorders Association (ADRDA) published clinical criteria for the diagnosis of AD. These organizations defined three categories: Possible AD, Probable AD and Definite AD.

The only difference between Probable and Definite AD is that the Definite AD category requires a brain biopsy confirming the presence of characteristic neurofibrillary tangles. While Definite AD is invariably only confirmed at autopsy, in approximately 85% of those with a diagnosis of Probable AD, pathological findings are found to be consistent.

The clinical criteria currently used for AD in patients with probable AD provide a sensitivity of approximately 85% when compared to autopsy confirmed cases (Definite AD). Therefore, a biomarker should have a sensitivity approaching or exceeding this value. A biomarker should have a specificity of 75% to 85% or greater, and the positive predictive value should be 80% or more.

There are currently no biomarkers that meet the above criteria. To date, all studies have focused on the use of biomarkers with Probable AD. The clinical utility of biomarkers may be greatest in patients with Possible AD, where the diagnosis is more uncertain. Few studies have focused on the use of biomarkers in patients with Possible AD with any follow up to determine the sensitivity and specificity of these markers in earlier stages of the disease.

The use of biomarkers will continue to be of interest to distinguish early AD from other causes of mild cognitive impairment, such as normal aging, vascular dementia or alcohol-related cognitive disorders. Research in patients with incipient AD is challenging because of the long follow-up required, and the possibility that any control group will also have patients with unrecognized incipient AD. There are inadequate data to determine how the results of these tests could be used to improve patient management, particularly given the limited treatment options. If ongoing research developing drugs targeting early stages of AD comes to fruition, then biomarkers to identify treatment candidates may have an impact on patient management.

The Alzheimer's Association and the National Institute on Aging (NIA), an agency of the U.S. National Institutes of Health (NIH), agree there are currently no validated biomarkers for Alzheimer's disease. They have jointly issued four new criteria and guidelines to diagnose Alzheimer's disease. Three of the four new criteria and guidelines that came out as a result of the research that the Alzheimer's Association and the National Institute on Aging (NIA) completed in April 2011 focus on three stages of Alzheimer's disease: 1) dementia due to Alzheimer's, 2) mild cognitive impairment (MCI) due to Alzheimer's, and 3) preclinical (presymptomatic) Alzheimer's. The 4th guideline updates criteria for documenting and reporting Alzheimer's related changes observed during an autopsy.

According to the research completed by these two agencies in 2011 "In the future, biomarker evidence may provide additional diagnostic certainty, but much more research is needed to identify

	MEDICAL COVERAGE POLICY	
Scott&White HEALTH PLAN PART OF BAYLOR SCOTT & WHITE HEALTH / FirstCare HEALTH PLANS PART OF BAYLOR SCOTT & WHITE HEALTH	**SERVICE:** Biochemical Markers of Alzheimers Disease	
	Policy Number:	029
	Effective Date:	11/01/2020
	Last Review:	09/24/2020
	Next Review Date:	09/24/2021

the most accurate biomarkers and confirm their usefulness. " Please see
http://www.alz.org/research/diagnostic_criteria/ for more information.

MANDATES: None

CODES:

Important note:
CODES: Due to the wide range of applicable diagnosis codes and potential changes to codes, an inclusive list may not be presented, but the following codes may apply. Inclusion of a code in this section does not guarantee that it will be reimbursed, and patient must meet the criteria set forth in the policy language.

CPT Codes:	
CPT Not Covered:	For this indication: 83015, 83018, 83520, 83825
ICD-10 codes:	F01.50 - F03.91 Dementia F07.0 - F07.9 Personality and behavioral disorders due to known physiological condition G30.0 - G30.9 Alzheimer's disease Z13.858 - Encounter for screening for other nervous system disorders [screening for dementia

CMS: No NCDs or LCDs have been issued.

POLICY HISTORY:

Status	Date	Action
New	12/6/2010	New policy
Reviewed	12/6/2011	Reviewed.
Reviewed	10/25/2012	Reviewed.
Reviewed	10/3/2013	Checked for updated Hayes rating.
Reviewed	07/24/2014	No changes
Reviewed	08/11/2015	No changes
Reviewed	08/18/2016	No changes
Reviewed	07/18/2017	Updated "Overview" section and coding.
Reviewed	05/29/2018	No changes
Reviewed	08/22/2019	Added list of studies not medically necessary
Reviewed	09/24/2020	Re-formatted for SWHP/FirstCare

REFERENCES:

The following scientific references were utilized in the formulation of this medical policy. SWHP/FirstCare will continue to review clinical evidence related to this policy and may modify it at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available and they are not included in the list, please forward the reference(s) to SWHP/FirstCare so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order.

1. NIH – Differential Diagnosis of Dementing Diseases #63. Consensus Statement from the NIH Consensus Development Program (1987 July 6-8) 6(11):1-27.
2. Arai, H., Terajima, M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Annuals of Neurology (1995 October) 38(4):649-652.

MEDICAL COVERAGE POLICY		
SERVICE:	Biochemical Markers of Alzheimers Disease	
Policy Number:	029	
Effective Date:	11/01/2020	
Last Review:	09/24/2020	
Next Review Date:	09/24/2021	

3. Motter, R., Vigo-Pelfrey, C., et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Annuals of Neurology (1995 October) 38(4):643-648. Available at http://onlinelibrary.wiley.com/doi/10.1002/ana.410380413/abstract

4. Galasko, D., Clark, C., et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology (1997 December) 48(3):632-635.

5. Green, R.C., Clarke, V.C., et al. Early detection of Alzheimer disease: methods, markers, and misgivings. Alzheimer's Disease and Associated Disorder (1997) 11(Supplement)5:S1-5.

6. NIA – National Institutes on Aging Progress Report on Alzheimer's Disease (1998 November) 99-3616: 1-51. Alzheimer's Disease Education and Referral (ADEAR) Center. Available at <http://www.alzheimers.org>

7. Hock, C., Drasch, G., et al. Increased blood mercury levels in patients with Alzheimer's disease. Journal of Neural Transmission (1998) 105(1):59-68.

8. Busser, J., Gelddmacher, D.S., et al. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. Journal of Neuroscience (1998 April 15) 18(8):2801-7.

9. Kanai, M., Matsubara, E., et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Annals of Neurology (1998 July) 44(1):7-26.

10. Hock, C., Golombowski, S., et al. Histological markers in nasal mucosa in patients with Alzheimer's disease. European Neurology (1998 July) 40(1):31-6.

11. Mecocci, P., Cherubini, A., et al. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer's disease? Alzheimer's Disease and Associated Disorder (1998 September) 12(3):211-4.

12. Kurz, A., Riemenschneider, M., et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer's disease. Alzheimer's Disease and Associated Disorders (1998 December) 12(4):372-7.

13. Genetic Testing for Alzheimer's Disease: APOE Epsilon 4 Allele. Chicago, Illinois: Blue Cross Blue Shield Association – Technology Evaluation Center Assessment Program (1999 June) 14(7):1-61.

14. Kahle, P.J., Jakowec, M., et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology (2000 October) 54(7):1498-504.

15. De La Monte, S., and J. Wands. The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. Frontier of Bioscience (2002 April) 7:989-96.

16. Carta, P., Flore, C., et al. Neuroendocrine and neurobehavioral effects with exposure to low doses of mercury from habitual consumption of marine fish. Medical Lavara (2002 May-June) 93(3):215-24.

17. Buerger, K., Zinkowski, R., et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Archives of Neurology (2002 August) 59(8):1267-72.

18. Munzar, M., Levy, S., et al. Clinical study of a urinary competitive ELISA for neural thread protein in Alzheimer Disease. Neurological Clinical Neurophysiology (2002 September) 2002(1):2-8.

19. Reimenschneider, M., Lautenschlager, N., et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Archives of Neurology (2002 November) 59(11):1729-34.

20. Andreasen, N., Vanechelen, E., et al. Cerebrospinal fluid levels pf total-tau, phosphor-tau and and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurology Scandavian Supplement (2003) 179:47-51.

21. Sunderland, T., Linker, G., et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Journal of the American Medical Association (2003 April) 289(16):2094-103.

22. Yokoo, E., Valente, J., et al. Low level methyl mercury exposure affects neuropsychological function in adults. Environmental Health (2003 June) 2(1):8.

23. Hampel, H., Goernitz, A., et al. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta (1-42) proteins to phosphorylated tau protein. Brain Research Bulletin (2003 August) 61(3):243-53.

24. Maddalena, A., Papassotiropoulos, A., et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta¬amyloid peptide 42. Archives of Neurology (2003 September) 60(9):1202-6.

	MEDICAL COVERAGE POLICY
Scott&White HEALTH PLAN PART OF BAYLOR SCOTT & WHITE HEALTH FirstCare HEALTH PLANS PART OF BAYLOR SCOTT & WHITE HEALTH	**SERVICE:** Biochemical Markers of Alzheimers Disease
	Policy Number: 029
	Effective Date: 11/01/2020
	Last Review: 09/24/2020
	Next Review Date: 09/24/2021

25. Parnetti, L., Lanari, L., et al. Cerebrospinal fluid in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Neurological Science (2003 October) 24(3):199-200.
26. Tsuboi, Y., Wszolek, Z., et al. Tau Pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathological Applied Neurobiology (2003 October) 29(5):503-10.
27. Hampel, H., Buerger, K., et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebral spinal fluid study. Archives of General Psychiatry (2004 January) 61(1):95-102.
28. Attems, J., and K. Jellinger. Only cerebral amyloid angiopathy correlates with Alzheimer pathology: A pilot study. Acta Neuropathology (2004 February) 107(2):83-90.
29. Hampel, H., Mitchell, A., et al. Core Biological marker candidates of Alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity. Journal of Neurological Transmission. (2004 March) 111(3):27-72.
30. Kim, K., Jung, G., et al. Increased Urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease. Brain Research Bulletin (2004 July) 64(1):47-51.
31. Ganguli, M., Dodge, H.H., et al. Mild cognitive impairment, amnestic type: An epidemiologic study. Neurology (2004 July) 63(1):115-21.
32. Mutter, J., Naumann, J., et al. Alzheimer disease: mercury as pathogenesis factor and apolipoprotein E as moderator. Neuro Endocrinology Letter (2004 October) 25(5):31-9.
33. Weil, M., Bressler, J., et al. Blood Mercury levels and neurobehavioral function. Journal of the American Medical Association (2005 April) 294(6):1875-82.
34. Attems, J., Lintner, F., et al. Olfactory involvement in aging and Alzheimer's disease: an autopsy study. Alzheimer's Disease (2005 April) 7(2):173-80.
35. Willams, S., Chambers, K., et al. Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathological Applied Neurobiology (2005 August) 31(4):414-21.
36. Paraskevas, G., Kapaki, E., et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. Journal of Geriatric Psychiatry and Neurology (2005 September) 18(3):163-73.
37. Parnetti, L., Lanari, A., et al. Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. Mechanical Ageing Development (2006 February) 127(2):129-32.
38. Hansson O., Zetterberg, H., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology (2006 March) 5(4):228-34.
39. Ibach, B., Binder, H., et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiology of Aging (2006 September) 27(9):1202-11.
40. Jeynes, B., and J. Provias. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Acta Neuropathology (2006 October) 112(4):417-27.
41. Blasko, I., Lederer, W., et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dementia Geriatric Cognitive Disorder (2006 October) 21(1):9-15.
42. Yokel, R. A. Blood-brain Barrier Flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. Journal of Alzheimer's Disease (2006 November) 10(2-3):223-253.
43. Attems, J., and K. Jellinger. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clinical Neuropathology (2006 November-December) 25(6):265- 71.
44. Stefani, A., Martoana, A., et al. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Neurological Science (2006 December) 251(1-2):124-8.
45. USPSTF – Screening for Dementia: Recommendations and Rationale (2003). U.S. Preventative Services Task Force.
46. Goodman, I., Golden, G., et al. A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease. Journal of the American Medical Director Association (2007 January) 8(1):21-30.
47. Lace, G., Wharton, S., et al. A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clinical Neuropathology (2007 March-April) 26(2):43-58.

	MEDICAL COVERAGE POLICY
	SERVICE: Biochemical Markers of Alzheimers Disease
	Policy Number: 029
	Effective Date: 11/01/2020
	Last Review: 09/24/2020
	Next Review Date: 09/24/2021

48. What is Alzheimer's? (2007). Alzheimer's Association
49. AA – Definition of Alzheimer's (2007). Alzheimer's Foundation of America (accessed - 2007 June 1). Available at <http://www.alzfdn.org>.
50. Takeda, M., Okochi, M., et al. Biological markers as outcome measures for Alzheimer's interventions-real problems and future possibilities. Institute Psychogeriatric (2007 March) 19 (3):391-400.
51. Bouwman, F.H., Schoonenboom, S.N., et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiology of Aging (2007 July) 28(7):1070-4.
52. Schoonenboom, N.S.M., Van De Flier, W.M., et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiology of Aging 2008 May; 29(5); 669-675
53. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4):385-93.
54. Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73(4):287-93.
55. Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009 Jul 28; 73(4):294-301.
56. McEvoy, Linda K & Brewer, James B. Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med. 2012; 4(3): 343-357.
57. Update on Dementia Edited by Davide Vito Moretti, ISBN 978-953-51-2655-3, Print ISBN 978-953-51-2654-6, 556 pages, Publisher: InTech, Chapters published September 28, 2016 under CC BY 3.0 license DOI: 10.5772/61983